Call us 24/7

Clinical trials


42 Clinical Trials

This is a phase II, randomized, double-blind, placebo-controlled, multi-center, comparative global study to determine the efficacy and safety of durvalumab-olaparib combination therapy vs. durvalumab-placebo (durvalumab monotherapy) as a first-line treatment in patients ineligible for platinum-based chemotherapy with unresectable stage IV urothelial cancer.


Accepting new patients


Learn more at

The main purpose of this study is to evaluate the anti-tumor activity of NKTR-214 in combination with nivolumab by assessing the objective response rate in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients with low PD-L1 expression. The efficacy will be assessed within the experimental Arm A, while Arm B will serve as a reference arm.